OTCMKTS:ICOTF iCo Therapeutics (ICOTF) Stock Price, News & Analysis → Jeff Bezos Just Humiliated Elon Musk (From InvestorPlace) (Ad) Free ICOTF Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$0.30▼$0.3250-Day Range$0.30▼$0.4252-Week Range$0.80▼$1.82Volume103,130 shsAverage Volume4,760 shsMarket Capitalization$2.90 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get iCo Therapeutics alerts: Email Address Ad The Oxford Club2024 Oil BoomWall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.All the details are right here About iCo Therapeutics Stock (OTCMKTS:ICOTF)Satellos Bioscience, Inc. is a regenerative medicine company, which engages in developing novel therapeutics. It operates through a proprietary technology platform, MyoReGenX™ and Leveraging MyoReGenX™, which identify stem cell based regeneration deficits in muscle diseases and develop therapeutic solutions. The company was founded by Frank Gleeson and Michael Rudnicki in 2018 and is headquartered in Toronto, Canada.Read More Ad The Oxford Club2024 Oil BoomWall Street’s betting on new oil bull market… JP Morgan analysts have pegged the future price of oil at $380 per barrel. That would send oil companies skyrocketing.All the details are right here ICOTF Stock News HeadlinesMay 10, 2023 | wsj.comICO Group Ltd.February 25, 2023 | marketwatch.comAntisense & RNAi Therapeutics Market 2023 Estimated to Perceive Exponential Growth till 2028May 6, 2024 | InvestorPlace (Ad)Jeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.February 19, 2023 | finance.yahoo.comWomen's health therapeutics market size to increase by USD 30.35 billion: North America to account for 37% of market growth - TechnavioFebruary 19, 2023 | seekingalpha.comJasper Therapeutics releases promising early-stage data on sickle cell disease treatmentOctober 10, 2022 | usnews.comConsumers to Ditch Cafes for Coffee at Home Amid Rising Prices, Says ICOAugust 16, 2022 | investing.comSatellos Bioscience Inc (MSCL)June 1, 2022 | seekingalpha.comSatellos Bioscience GAAP EPS of -C$0.06May 6, 2024 | InvestorPlace (Ad)Jeff Bezos Just Humiliated Elon MuskThe Next Nvidia? Wall Street legend has just uncovered one tiny Maryland company that could become the next Nvidia. Few in the media are talking about this story yet… but in the next 6 months that’s all they’ll talk about.December 16, 2021 | finance.yahoo.comSatellos Bioscience Inc. Announces Scientific Research Agreement with Université de Sherbrooke to Study Rare Muscular DystrophiesDecember 15, 2021 | finance.yahoo.comSatellos Bioscience to Webcast Live at Life Sciences Investor Forum December 16thDecember 9, 2021 | finance.yahoo.comICOTF: Targeting Stem Cells for Muscular Dystrophy TreatmentDecember 6, 2021 | finance.yahoo.comSatellos Bioscience Announces New Board AppointmentsDecember 2, 2021 | investing.comiCo Therapeutics Inc (MSCL)November 29, 2021 | finance.yahoo.comSatellos Bioscience Reports Third Quarter 2021 Financial Results and Operational HighlightsOctober 27, 2021 | finance.yahoo.comSatellos Bioscience Inc. Retains BND Projects Inc. for Strategic Investor Relations ServicesAugust 5, 2021 | finance.yahoo.comiCo Therapeutics Inc. Announces Shareholder Approval of Business Combination with Satellos Bioscience Inc.See More Headlines Receive ICOTF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for iCo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Today5/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolOTCMKTS:ICOTF CUSIPN/A CIKN/A Webwww.icotherapeutics.com Phone(905) 336-6128Fax604-602-9699EmployeesN/AYear FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.40) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-1,110,000.00 Net MarginsN/A Pretax Margin-4,148.78% Return on EquityN/A Return on Assets-288.85% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-4.57Miscellaneous Outstanding Shares9,054,000Free FloatN/AMarket Cap$2.90 million OptionableNot Optionable Beta2.03 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesFrank GleesonPresident & Chief Executive OfficerWarren WhiteheadChief Financial OfficerMichael RudnickiChief Scientific OfficerJ. Robert HallVice President-Finance & AdministrationKey CompetitorsBiophytisNASDAQ:BPTSAraviveNASDAQ:ARAVAridis PharmaceuticalsNASDAQ:ARDSAvenue TherapeuticsNASDAQ:ATXIVirpax PharmaceuticalsNASDAQ:VRPXView All Competitors This page (OTCMKTS:ICOTF) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersNo experience to confident trader, meet my student…Wealth Builders InstituteBiden’s $374B Giveaway Into This SectorDTIAI “wealth window” is closing June 25thParadigm Press2024 Oil BoomThe Oxford ClubMake this ONE trade on Tuesday at 2 p.m. EST!Monument Traders AllianceWarren Buffet Stockpiling Gold?Reagan Gold GroupControversial CEO explains new way to amass wealthStansberry ResearchThe 2024 crypto bull run has already started — don’t get left behindInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iCo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
